New deal to model immune therapy for cancer with global biopharmaceutical company
Physiomics is pleased to announce that it has signed a new contract with a global pharmaceutical company. The project will involve adapting the existing Virtual Tumour to model immunomodulatory agents, currently a significant focus of cancer research. The initial phase of the project will be focused on making pre-clinical predictions. If successful, the project may be extended to also adapt Virtual Tumour Clinical to immune therapies in cancer. The initial project will start immediately and will be completed by the end of 2014.